Transplant; Failure, Kidney
Conditions
Brief summary
Purpose of the study: The specific aims of this study are to evaluate overall efficacy and safety of the pre-transplant IVIG treatment in our transplant center since 2007 and to identify factors affecting treatment outcomes in order to improve patient selection and treatment protocols for future patients.
Detailed description
Background: Intravenous immunoglobulin (IVIG) infusion is one of several novel approaches to decrease antibody levels for highly sensitized kidney transplant candidates \[1, 2\]. This approach can potentially give a chance of kidney transplantation to end-stage renal failure patients who could never receive transplantation because of high levels of antibodies and persistent positive crossmatches to all potential kidney donors. Many transplant centers have used this strategy in order to increase transplant rates of highly sensitized patients with various levels of anti-HLA antibodies. However, the responses to the treatment seem to be different in each patient and factors affecting treatment outcome have yet to be determined.
Interventions
None listed
Sponsors
University of Miami
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
7 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Recent (\< 3 months) high levels of anti-HLA antibodies (at least one cPRA ≥ 40%). * Waiting time greater than 1 year for blood type AB, 2 years for blood types A, B, or O.
Exclusion criteria
* Female subject is pregnant or lactating. * Subject has an uncontrolled concomitant infection or any other unstable medical condition (e.g., uncontrolled cardiovascular disease) that could interfere with the study objectives. * Subject has an uncontrolled active hepatitis B, hepatitis C, or HIV infection. * Subject has a current malignancy or a recent history of any malignancy that is deemed to be contraindicated to kidney transplantation. * Subject has a psychiatric illness that, in the judgment of caring physicians, may interfere with study participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anti HLA antibody level | after IVIG infusion |
Secondary
| Measure | Time frame |
|---|---|
| Number of patients transplanted | at the end of study |
Countries
United States
Outcome results
None listed